Home' Australian Pharmacist : Australian Pharmacist Oct 2013 Contents 76 Australian Pharmacist October 2013 I ©Pharmaceutical Society of Australia Ltd.
BUSINESS AND INDUSTRY NEWS
eMIMS, one of the most comprehensive
digital sources of drug information in
Australia, now boasts it is an even more
advanced digital source.
One of the major innovations of the new
product is its delivery platform with the
new eMIMSCloud currently available
and with eMIMSDesktop to follow later
in the year. A modern interface and
simple functionality is shared across both
delivery platforms as is the resource rich
content. What differs is simply the way
MIMS delivers each version.
eMIMSCloud is internet based; users
can key, click or touch. Being able to use
eMIMSCloud on a PC, MAC or Android
and on desktop, laptop or tablet has
opened up wonderful opportunities for
mobility. The desktop is locally installed
meaning that users do not need internet
connectivity to access all the content and
functionality of the new eMIMS.
Siobhan Murphy Country Manager for
MIMS said, 'Because we understand
that many of our customers are not yet
ready to use an internet based resource
we made a decision to support that
thinking and have developed the new
eMIMS as both an internet based and a
eMIMS has a broad breadth of content
including evidence-based drug
interactions, patient care and clinical
resources as well as the most refined
image search capabilities have all been
put together in a way that will encourage
engagement with patients and support
eMIMS is designed to be a comprehensive
resource, supporting pharmacists and
clinicians across their work flow.
Also available as an additional module
in the new eMIMS is the IMgateway
herb-drug, supplement-drug and
food-drug interactions database.
Botox boost for Allergen
The approval of Botox by the Federal
Drug Authority, albeit for cosmetic use on
crows' feet, is a boost Allergen.
Allergan aid that with the FDA approval,
Botox Cosmetic was the first and only
drug of its kind to temporarily treat
moderate to severe lateral canthal lines,
commonly known as "crow's feet" lines.
When Allergan first mooted that it would
seek approval for Botox in this category,
estimates were that it could add about
$100 million in sales for the drug, which
was approved in 2002 for cosmetic use on
frown lines between the brows.
In June this year, Allergan was caught
off-guard by the FDA's draft guidelines
allowing generics of its eye drug Restasis
onto the market without clinical testing,
years ahead of what the company or
industry analysts had expected.
This hit the company hard and because
Restasis last year was the company's
biggest seller, with sales of more than
Allergen last month asked the FDA to
raise the standard for approving generic
versions by requiring testing in humans.
Allergen says generic versions can't be
deemed bioequivalent unless they have
been tested and approved in human
patients. Further it claimed the FDA's last
proposal to permit only lab testing was
contrary its previous stances and rulings.
The company and FDA also haven't seen
eye-to-eye recently over the FDA's refusal
to approve Allergen's new migraine drug
because of manufacturing problems.
In August, Allergan lost two patents in
India when the country's patent appeals
board revoked the patents covering
glaucoma treatments Ganfort and
Combigan, both used to reduce pressure
inside the eye, following a patent
challenge from domestic drugmaker
South Africa patent move
The South African government is
proposing a new national policy on
intellectual property which will raise the
bar on innovation, striking a blow at what
critics consider "evergreening" by drug
companies to extend patent protection.
South Africa currently doesn't examine
patent applications and just distributes
them, allowing drugmakers to get a
number of patents on the same drug.
Industry sources say that often the
patents are for items that don't
qualify under the country's definition
Fierce Pharma reported that in addition,
health groups that work with the poor,
like Medecins Sans Frontieres (MSF), say
that in 2008, South Africa granted 2,442
pharmaceutical patents, while a country
like Brazil approved only 278 in the five
years between 2003 and 2008.
This results in cheaper generics being
kept from getting on the market.
South Africa is one of those emerging
markets that Big Pharma has eyeing for
But the governments of some emerging
markets like China, South Africa and Brazil
are learning from the battles fought over
patents in India.
China last month yanked the patent on
Gilead Sciences' popular HIV and hepatitis
B drug Viread (tenofovir) on a challenge
from a generic drugmaker there. The
move is expected to cut the price of the
drug in half.
However, the South African issue is still
I its early stages and the government
would have to create and fund a much
more sophisticated process for evaluating
and granting patents.
China investigates Bayer
Bayer has confirmed Chinese officials
have instigated a probes into a potential
case of unfair competition.
Oliver Renner, head of global corporate
communications and public affairs at the
German major, was reported in Pharma
Times as saying that a local branch of
the AIC (Administration for Industry and
Commerce) 'visited one of our offices in
China at the end of August to investigate
a potential case of unfair competition'.
He went on to say, 'we are fully
cooperating with the authority and
Bayer is committed to investigating the
No further details have been disclosed
which comes as part of China's
investigations into the pharmaceutical
sector as a whole regarding
Links Archive Australian Pharmacist Sept 2013 Australian Pharmacist Nov 2013 Navigation Previous Page Next Page